IP Library Granted Patent US 47,121
Granted Patent E1
US 47,121 · App. 14/334,294 · Granted Nov 13, 2018

Embolic compositions

Inventors: Dennis W. Goupil (Norcross, GA); Hassan Chaouk (Atlanta, GA); Troy Holland (Suwanee, GA); Bruktawit T. Asfaw (Atlanta, GA); Stephen D. Goodrich (Norcross, GA); Lucas Latini (Norcross, GA)
Assignee: BioCure, Inc.
A61B17/12022A61B17/1219A61B17/12099A61B17/12113A61B17/12122A61B17/12186A61B17/12195A61L24/0031A61L24/06A61L27/16A61L27/34A61L27/52A61L29/041A61L31/048A61L31/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 47,121
App. No.
14/334,294
Granted
Nov 13, 2018
Kind
E1
Abstract

Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.

Claims (24)

1. A method for embolization, comprising the steps:

providing a composition comprising macromers having a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure and at least two pendant chains bearing crosslinkable groups and having the formula:

in which R is a linear or branched C 1 -C 8 alkylene or a linear or branched C 1 -C 12 alkane; R 1 is hydrogen, a C 1 -C 6 alkyl, or a cycloalkyl; R 2 is hydrogen or a C 1 -C 6 alkyl; and R 3 is an olefinically unsaturated electron attracting copolymerizable radical having up to 25 carbon atoms;

delivering the composition to the intended site of embolization, or upstream of the intended site; and

then crosslinking the macromers to form a hydrogel;

wherein the crosslinkable groups of the macromer are crosslinkable via free radical polymerization that is redox initiated;

and the composition comprises a first solution comprising a reductant and a second solution comprising an oxidant and the macromers are present in either or both solutions.

2. The method of claim 1 , wherein the macromere macromer further comprises pendant modifier groups.

3. The method of claim 1 , further comprising administering an active agent.

4. The method of claim 3 , wherein the active agent is a chemotherapeutic agent.

5. The method of claim 1 , wherein the hydrogel is biodegradable.

6. The method of claim 1 , wherein the composition further comprises a copolymerizable monomer.

7. The method of claim 1 , wherein the method comprises using a delivery device to deliver the solutions separately and mixing the solutions to initiate crosslinking.

8. The method of claim 7 wherein the solutions are delivered to the intended site using a multilumen catheter.

9. The method of claim 8 wherein the solutions are mixed in the catheter.

10. The method of claim 1 , wherein the embolization is used for treatment of a uterine fibroid, by delivering the embolic composition to a vessel feeding the fibroid to occlude the vessel.

11. The method of claim 1 , wherein the embolization is used for treatment of a tumor, by delivering the embolic composition to a vessel feeding the tumor to occlude the vessel.

12. The method of claim 1 , wherein the embolization is used for treatment of an endoleak by delivering the embolic composition to seal the endoleak.

13. The method of claim 12 , wherein scaling the endoleak comprises partially or completely filling the aneurysm sac with the embolic composition.

14. The method of claim 1 , wherein the embolization is used for treatment of an arteriovenous malformation by delivering the embolic composition to occlude the malformation.

15. The method of claim 1, further comprising delivering an occlusive device to the intended site of embolization before, during, or after the embolic composition is administered.

16. The method of claim 15, wherein the macromers have a cellular adhesion promoter attached thereto.

17. The method of claim 1, wherein the composition includes a contrast agent.

18. The method of claim 1, wherein the macromers have a molecule attached thereto that allows visualization of the formed hydrogel.

Continuity (5)
Reissue 12386828 · Apr 23, 2009
Division 10465497 · Jun 19, 2003
Division 09804963 · Mar 13, 2001
Provisional Application 60188975 · Mar 13, 2000
Provisional Application 60254697 · Dec 11, 2000